The Cytoplasmic Prolyl-tRNA Synthetase of the Malaria Parasite is a Dual-Stage Target for Drug Development

@inproceedings{Herman2015TheCP,
  title={The Cytoplasmic Prolyl-tRNA Synthetase of the Malaria Parasite is a Dual-Stage Target for Drug Development},
  author={Jonathan D. Herman and Lauren R. Pepper and Joseph F. Cortese and Guillermina and Estiu and Kevin Galinsky and Vanessa Zuzarte-Lu{\'i}s and Emily R Derbyshire and Ulf Ribacke and Amanda K Lukens and Sofia Alexandre Santos and Vishal V. Patel and Clary B Clish and Josette William and Sullivan and Huihao Zhou and Selina E. R. Bopp and Paul R. Schimmel and Susan Lindquist and Jon Clardy and Maria M Mota and Tracy L. Keller and Malcolm Whitman and Olaf Wiest and Dyann F Wirth and Ralph Mazitschek},
  year={2015}
}
The emergence of drug resistance is a major limitation of current antimalarials. The discovery of new druggable targets and pathways including those that are critical for multiple life cycle stages of the malaria parasite is a major goal for the development of the next-generation of antimalarial drugs. Using an integrated chemogenomics approach that combined drug-resistance selection, whole genome sequencing and an orthogonal yeast model, we demonstrate that the cytoplasmic prolyl-tRNA… CONTINUE READING

Figures from this paper.

References

Publications referenced by this paper.
SHOWING 1-10 OF 66 REFERENCES

Antimalarial activities and therapeutic properties of febrifugine analogs.

  • Antimicrobial agents and chemotherapy
  • 2005
VIEW 5 EXCERPTS
HIGHLY INFLUENTIAL